The current demographics in UK make it an ideal market as the demand for anti-aging and overall skincare products is high thereby resulting in the growth of the UK anti-aging market during the forecast period. The market is segmented by product type, service type, route of administration and device type.
The US breast cancer market is expected to witness growth from $473 Mn in 2022 to $1,083 Mn in 2030 with a CAGR of 10.9% for the year 2022-2030. Increased prevalence of breast cancer and technologically advanced therapeutics are the major growth drivers for the expansion of the market in US.
The APAC EHR market is projected to grow from $5.94 Bn in 2022 to $8.96 Bn in 2030 with a CAGR of 5.27% for the year 2022-2030. The introduction of artificial intelligence in the advancement of EHR has significantly contributed to the growth of the market. McKesson Corporation and Oracle Cerner Corporation are the major players in the APAC EHR market.
The India osteoporosis drugs market is projected to grow during the forecast period because of the high incidence of osteoporosis in India and due to the rising geriatric population. The market is segmented by drug class and by route of administration. Some of the key players in the market are Cadila pharmaceuticals and Dr. Reddy's Laboratories.
The Japan telemedicine market is projected to grow from $3.77 Bn in 2022 to $14.89 Bn in 2030 with a CAGR of 18.7% for the year 2022-2030. Tele monitoring, tele consulting, and tele education are major types of telemedicine services in Japan. The market is segmented by product and by application.
The Global Cholangiocarcinoma market is expected to witness growth as the incidence of Cholangiocarcinoma is rising globally. The market is segmented by treatments, distribution channels, and regions. Incyte Corporation and Eisai are the key players in the Global Cholangiocarcinoma market.
The growing prevalence of Alzheimer's disease in elderly women in Australia is responsible for the growth of Australia Alzheimer's disease market. The market is segmented by product, drug, and distribution channel. Roche, Eisai, and Novartis are some of the key competitors in the market.
The Germany patient support programs market is expected to grow during the forecast period as more and more pharma companies are investing in patient support programs in Germany. The market is segmented by functionality outlook, therapeutic area outlook, application outlook, and by end users.
The Italy patient support programs market is projected to grow during the forecast period as the demand for patient-centric care is increasing in Italy. PSOLife care by Novartis, Hemozone by BioVIIIx, and Clickservice by Merck are major pharma-sponsored PSPs in Italy.
The Spain patient support programs market is growing as the demand for personalized medicine increases in Spain. Major PSP operators in Spain are Ashfield Engage, Videnze, Clover, Martifarm and Alcura.
The France patient support programs market is expected to grow as many of pharma companies are investing in the market in France. The market is segmented by functionality outlook, therapeutic area outlook, application outlook, and the end user. Major services include caregiver access, healthcare financing, and self-care.
The UK patient support programs is expected to witness growth as the demand for more personalized medicine and care is increasing in the UK. Patients and Healthcare Services by Biogen and Together Enbrel Patient Support Program by Pfizer are some of the major pharma-sponsored PSPs in UK.